PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32759497-4	2020	Here we show that low-dose RAD001/everolimus, an mTORC1 inhibitor, selectively targets mTORC1 signaling in endothelial cells (ECs) without affecting tumor cells or immune cells, resulting in tumor vessel normalization and increased antitumor immunity.	Everolimus	27-33	CREB regulated transcription coactivator 1	Mus musculus	49-55	
32759497-4	2020	Here we show that low-dose RAD001/everolimus, an mTORC1 inhibitor, selectively targets mTORC1 signaling in endothelial cells (ECs) without affecting tumor cells or immune cells, resulting in tumor vessel normalization and increased antitumor immunity.	Everolimus	27-33	CREB regulated transcription coactivator 1	Mus musculus	87-93	
32759497-4	2020	Here we show that low-dose RAD001/everolimus, an mTORC1 inhibitor, selectively targets mTORC1 signaling in endothelial cells (ECs) without affecting tumor cells or immune cells, resulting in tumor vessel normalization and increased antitumor immunity.	Everolimus	34-44	CREB regulated transcription coactivator 1	Mus musculus	49-55	
32759497-4	2020	Here we show that low-dose RAD001/everolimus, an mTORC1 inhibitor, selectively targets mTORC1 signaling in endothelial cells (ECs) without affecting tumor cells or immune cells, resulting in tumor vessel normalization and increased antitumor immunity.	Everolimus	34-44	CREB regulated transcription coactivator 1	Mus musculus	87-93